MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 533066 | Name: SRT3025 HCl
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SRT3025 is a Novel Sirtuin1 Activator, Down-Regulating Sclerostin and Rescuing Ovariectomy-Induced Bone Loss.

Chemical Structure

SRT3025 HCl
CAS#2070015-26-6 (HCl)

Theoretical Analysis

MedKoo Cat#: 533066

Name: SRT3025 HCl

CAS#: 2070015-26-6 (HCl)

Chemical Formula: C31H32ClN5O2S2

Exact Mass: 0.0000

Molecular Weight: 606.20

Elemental Analysis: C, 61.42; H, 5.32; Cl, 5.85; N, 11.55; O, 5.28; S, 10.58

Price and Availability

Size Price Availability Quantity
5mg USD 150.00 Ready to ship
10mg USD 250.00 Ready to ship
25mg USD 450.00 Ready to ship
50mg USD 750.00 Ready to ship
100mg USD 1,250.00 Ready to ship
200mg USD 1,950.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
1231952-55-8 (free base) 2070015-26-6 (HCl)
Synonym
SRT3025; SRT-3025; SRT 3025; SRT3025 HCl; SRT3025 hydrochloride
IUPAC/Chemical Name
5-(3-Methoxypropyl)-2-phenyl-N-[2-[6-(1-pyrrolidinylmethyl)thiazolo[5,4-b]pyridin-2-yl]phenyl]-4-thiazolecarboxamide hydrochloride
InChi Key
LGRBDTOIPNDWMN-UHFFFAOYSA-N
InChi Code
InChI=1S/C31H31N5O2S2.ClH/c1-38-17-9-14-26-27(35-29(39-26)22-10-3-2-4-11-22)28(37)33-24-13-6-5-12-23(24)30-34-25-18-21(19-32-31(25)40-30)20-36-15-7-8-16-36;/h2-6,10-13,18-19H,7-9,14-17,20H2,1H3,(H,33,37);1H
SMILES Code
O=C(C1=C(CCCOC)SC(C2=CC=CC=C2)=N1)NC3=CC=CC=C3C4=NC5=CC(CN6CCCC6)=CN=C5S4.[H]Cl
Appearance
Fluffy yellow powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
Sirtuin modulator 1 is a modulator of SIRTl, a homolog of SIRT3, with EC1.5 of < 1 μM, extracted from patent WO 2010071853 A1, Compound No.4.
In vitro activity:
To investigate if the effects of Sirt1 on the marrow adipocyte phenotype can be extended to human BM-MSCs, SRT3025 was administered to primary human femoral BM-MSCs. Strikingly, SRT3025-treated human BM-MSCs had increased mRNA expression of PGC1α (Figure 6A) accompanied by elevated PGC1α protein level (Figure 6B), suggesting that Sirt1 activates PGC1α in human femoral BM-MSCs. Reference: Front Endocrinol (Lausanne). 2019 Feb 28;10:126. https://pubmed.ncbi.nlm.nih.gov/30873124/
In vivo activity:
Diabetic mice that had received SRT3025 had improved glycaemic control as manifested by lower HbA1c, fasting and non-fasting blood glucose concentrations (Fig. 1A,B). Fasting plasma insulin concentrations were below the limits of detection by ELISA in animals that had received STZ regardless of their assignment to receive SRT3025 or not and while detectable but very low in the non-fasting state, concentrations did not vary according to treatment assignment (Fig. 2A). Plasma glucagon was markedly elevated in untreated diabetic mice but was substantially reduced with SRT3025 (Fig. 2B). Reference: Sci Rep. 2018 Sep 18;8(1):13972. https://pubmed.ncbi.nlm.nih.gov/30228292/
Solvent mg/mL mM comments
Solubility
DMSO 56.3 92.79
Ethanol 5.0 8.25
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 606.20 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Artsi H, Gurt I, El-Haj M, Müller R, Kuhn GA, Ben Shalom G, Cohen-Kfir E, Abramowitz E, Kandel L, Safran O, Dresner-Pollak R. Sirt1 Promotes a Thermogenic Gene Program in Bone Marrow Adipocytes: From Mice to (Wo)Men. Front Endocrinol (Lausanne). 2019 Feb 28;10:126. doi: 10.3389/fendo.2019.00126. PMID: 30873124; PMCID: PMC6403178. 2. Zhang Y, Thai K, Jin T, Woo M, Gilbert RE. SIRT1 activation attenuates α cell hyperplasia, hyperglucagonaemia and hyperglycaemia in STZ-diabetic mice. Sci Rep. 2018 Sep 18;8(1):13972. doi: 10.1038/s41598-018-32351-z. PMID: 30228292; PMCID: PMC6143559. 3. Zhang QS, Deater M, Schubert K, Marquez-Loza L, Pelz C, Sinclair DA, Grompe M. The Sirt1 activator SRT3025 expands hematopoietic stem and progenitor cells and improves hematopoiesis in Fanconi anemia mice. Stem Cell Res. 2015 Jul;15(1):130-40. doi: 10.1016/j.scr.2015.05.007. Epub 2015 May 22. PMID: 26046330; PMCID: PMC4516677.
In vitro protocol:
1. Artsi H, Gurt I, El-Haj M, Müller R, Kuhn GA, Ben Shalom G, Cohen-Kfir E, Abramowitz E, Kandel L, Safran O, Dresner-Pollak R. Sirt1 Promotes a Thermogenic Gene Program in Bone Marrow Adipocytes: From Mice to (Wo)Men. Front Endocrinol (Lausanne). 2019 Feb 28;10:126. doi: 10.3389/fendo.2019.00126. PMID: 30873124; PMCID: PMC6403178.
In vivo protocol:
1. Zhang Y, Thai K, Jin T, Woo M, Gilbert RE. SIRT1 activation attenuates α cell hyperplasia, hyperglucagonaemia and hyperglycaemia in STZ-diabetic mice. Sci Rep. 2018 Sep 18;8(1):13972. doi: 10.1038/s41598-018-32351-z. PMID: 30228292; PMCID: PMC6143559. 2. Zhang QS, Deater M, Schubert K, Marquez-Loza L, Pelz C, Sinclair DA, Grompe M. The Sirt1 activator SRT3025 expands hematopoietic stem and progenitor cells and improves hematopoiesis in Fanconi anemia mice. Stem Cell Res. 2015 Jul;15(1):130-40. doi: 10.1016/j.scr.2015.05.007. Epub 2015 May 22. PMID: 26046330; PMCID: PMC4516677.
1: Miranda MX, van Tits LJ, Lohmann C, Arsiwala T, Winnik S, Tailleux A, Stein S, Gomes AP, Suri V, Ellis JL, Lutz TA, Hottiger MO, Sinclair DA, Auwerx J, Schoonjans K, Staels B, Lüscher TF, Matter CM. The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression. Eur Heart J. 2015 Jan 1;36(1):51-9. doi: 10.1093/eurheartj/ehu095. Epub 2014 Mar 6. PMID: 24603306; PMCID: PMC4286317. 2: Opal SM, Ellis JL, Suri V, Freudenberg JM, Vlasuk GP, Li Y, Chahin AB, Palardy JE, Parejo N, Yamamoto M, Chahin A, Kessimian N. PHARMACOLOGICAL SIRT1 ACTIVATION IMPROVES MORTALITY AND MARKEDLY ALTERS TRANSCRIPTIONAL PROFILES THAT ACCOMPANY EXPERIMENTAL SEPSIS. Shock. 2016 Apr;45(4):411-8. doi: 10.1097/SHK.0000000000000528. PMID: 26974318. 3: Wang X, Li S, Li Z, Lin Z, Wang Z. SRT3025-loaded cell membrane hybrid liposomes (3025@ML) enhanced anti-tumor activity of Oxaliplatin via inhibiting pyruvate kinase M2 and fatty acid synthase. Lipids Health Dis. 2025 Jan 17;24(1):14. doi: 10.1186/s12944-025-02431-x. PMID: 39825408; PMCID: PMC11740399. 4: Kim HN, Han L, Iyer S, de Cabo R, Zhao H, O'Brien CA, Manolagas SC, Almeida M. Sirtuin1 Suppresses Osteoclastogenesis by Deacetylating FoxOs. Mol Endocrinol. 2015 Oct;29(10):1498-509. doi: 10.1210/me.2015-1133. Epub 2015 Aug 19. PMID: 26287518; PMCID: PMC4588729. 5: Zhang Y, Thai K, Jin T, Woo M, Gilbert RE. SIRT1 activation attenuates α cell hyperplasia, hyperglucagonaemia and hyperglycaemia in STZ-diabetic mice. Sci Rep. 2018 Sep 18;8(1):13972. doi: 10.1038/s41598-018-32351-z. PMID: 30228292; PMCID: PMC6143559. 6: Zhang QS, Deater M, Schubert K, Marquez-Loza L, Pelz C, Sinclair DA, Grompe M. The Sirt1 activator SRT3025 expands hematopoietic stem and progenitor cells and improves hematopoiesis in Fanconi anemia mice. Stem Cell Res. 2015 Jul;15(1):130-40. doi: 10.1016/j.scr.2015.05.007. Epub 2015 May 22. PMID: 26046330; PMCID: PMC4516677. 7: Artsi H, Cohen-Kfir E, Gurt I, Shahar R, Bajayo A, Kalish N, Bellido TM, Gabet Y, Dresner-Pollak R. The Sirtuin1 activator SRT3025 down-regulates sclerostin and rescues ovariectomy-induced bone loss and biomechanical deterioration in female mice. Endocrinology. 2014 Sep;155(9):3508-15. doi: 10.1210/en.2014-1334. Epub 2014 Jun 20. PMID: 24949665; PMCID: PMC11651357. 8: Gurt I, Artsi H, Cohen-Kfir E, Hamdani G, Ben-Shalom G, Feinstein B, El-Haj M, Dresner-Pollak R. The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL- Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells. PLoS One. 2015 Jul 30;10(7):e0134391. doi: 10.1371/journal.pone.0134391. PMID: 26226624; PMCID: PMC4520518. 9: Veitch MR, Thai K, Zhang Y, Desjardins JF, Kabir G, Connelly KA, Gilbert RE. Late intervention in the remnant kidney model attenuates proteinuria but not glomerular filtration rate decline. Nephrology (Carlton). 2021 Mar;26(3):270-279. doi: 10.1111/nep.13828. Epub 2021 Jan 11. PMID: 33179827. 10: Chini CC, Espindola-Netto JM, Mondal G, Guerrico AM, Nin V, Escande C, Sola- Penna M, Zhang JS, Billadeau DD, Chini EN. SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway. Clin Cancer Res. 2016 May 15;22(10):2496-507. doi: 10.1158/1078-0432.CCR-15-1760. Epub 2015 Dec 11. PMID: 26655844; PMCID: PMC4867252.
1. Artsi H, Gurt I, El-Haj M, Müller R, Kuhn GA, Ben Shalom G, Cohen-Kfir E, Abramowitz E, Kandel L, Safran O, Dresner-Pollak R. Sirt1 Promotes a Thermogenic Gene Program in Bone Marrow Adipocytes: From Mice to (Wo)Men. Front Endocrinol (Lausanne). 2019 Feb 28;10:126. doi: 10.3389/fendo.2019.00126. PMID: 30873124; PMCID: PMC6403178. 2. Zhang Y, Thai K, Jin T, Woo M, Gilbert RE. SIRT1 activation attenuates α cell hyperplasia, hyperglucagonaemia and hyperglycaemia in STZ-diabetic mice. Sci Rep. 2018 Sep 18;8(1):13972. doi: 10.1038/s41598-018-32351-z. PMID: 30228292; PMCID: PMC6143559. 3. Zhang QS, Deater M, Schubert K, Marquez-Loza L, Pelz C, Sinclair DA, Grompe M. The Sirt1 activator SRT3025 expands hematopoietic stem and progenitor cells and improves hematopoiesis in Fanconi anemia mice. Stem Cell Res. 2015 Jul;15(1):130-40. doi: 10.1016/j.scr.2015.05.007. Epub 2015 May 22. PMID: 26046330; PMCID: PMC4516677.